Medicine composite used for treating pulmonary tuberculosis

A composition and a technology for pulmonary tuberculosis are applied in the field of pharmaceutical compositions for the treatment of pulmonary tuberculosis, can solve the problems of poor water solubility, limited application in the field of biomedicine, etc., and achieve the effects of remarkable effect, great clinical application value and social benefit, and suitability for industrialized production.

Inactive Publication Date: 2017-10-27
苏州瑞美科生物技术有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, based on the research on chitosan, it has been reported that it has various functions such as antibacterial, anti-tumor, regulating blood lipid, regulating immunity and promoting wound repair, but its poor water solubility greatly limits its application in the field of biomedicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composite used for treating pulmonary tuberculosis
  • Medicine composite used for treating pulmonary tuberculosis
  • Medicine composite used for treating pulmonary tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The preparation of embodiment 1 chitosan oligosaccharide (enzymatic method)

[0019] Chitosan 10g (deacetylation degree 95%, moisture 4.85%, ash content 0.5%, viscosity-average molecular weight 100,000, purchased from Jinan Haidebei Marine Engineering Co., Ltd.) was dissolved with acetic acid 333ml, and the chitosan concentration was 0.03g / ml, add 5ml of papain (enzyme content 45u) for hydrolysis, adjust the pH value to 6.1 after hydrolysis for 20mim, continue to degrade for 6h at 50°C, inactivate the enzyme for 15min at 100°C, centrifuge to get the supernatant, freeze-dry to obtain oligomeric chitosan Sugar 9.57g. Through HPLC test, it is confirmed that it is chitosan oligosaccharide, and its average molecular weight is 1200.

Embodiment 2

[0020] The preparation of embodiment 2 pharmaceutical composition

[0021] Chitosan oligomeric purity ≥ 98%, molecular weight 600-4000, embodiment 1 makes following each composition raw material all can buy:

[0022]

[0023]

[0024] Take a 200ml beaker, add 100ml of depyrogenated distilled water, then add 5g chitosan oligosaccharide, 1g Chuanbei extract, 0.8g Prunella vulgaris extract, 0.8g Bletilla striata extract, 0.5g Duheng extract, 0.5g Fenghancao extract 1. 0.5g of acanthus extract, fully stirred to make it evenly mixed, boiled for 5min, cooled to room temperature 25°C, and filtered to remove insoluble matter to obtain 109.1g of a pharmaceutical composition solution.

[0025] The pharmaceutical composition prepared in Example 2 was used in the following experiments.

Embodiment 3

[0026] Example 3 Acute Toxicity Test

[0027] Experimental animals: 70 Kunming mice, weighing 17-22 g, male and female, were purchased from Shanghai Slack Experimental Animal Co., Ltd.

[0028] Grouping of animals: The male and female were randomly divided into 7 groups with 10 animals in each group, one of which was a blank control group.

[0029] Experimental sample: prepared in Example 2.

[0030] Dosage determination: Dose design is 3ml / kg, 10ml / kg, 50ml / kg, 100ml / kg.

[0031] Administration: one-time intragastric administration: fasting for 3-5 hours before administration, fasting for 1-2 hours after administration, and fasting without water. Dosing in batches was adopted, the first batch of administration was given to the control group, 3ml / kg group, and 10ml / kg group. After administration, it was determined that the set dose was appropriate, and then 50ml / kg group and 100ml / kg group were administered. After administration, observe continuously for more than 7 days, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a medicine composite used for treating pulmonary tuberculosis. The medicine composite comprises the following components in parts by weight: 2-8 parts of oligochitosan, 0.5-2 parts of bulbus fritillariae cirrhosae extract, 0.5-1 part of prunella vulgaris extract, 0.5-1 part of bletilla extract, 0.25-0.75 parts of asarum forbesii extract, 0.25-0.75 parts of lysimachia christinae extract and 0.25-0.75 parts of gomphrena globosa extract. An acute toxicity experiment result indicates that the medicine composite can be deemed to be nontoxic; a bacteriostasis experiment verifies that the medicine composite has very high bacteriostasis capacity for mycobacteria and other pathogenic bacteria; and an animal experiment indicates that the medicine composite has a significant effect for treating the pulmonary tuberculosis. Therefore, the medicine composite can be used for treating the pulmonary tuberculosis, and has a larger clinical application value and a larger social benefit. The medicine composite is simple in preparation method, and is suitable for industrial production.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating pulmonary tuberculosis. Background technique [0002] Tuberculosis is still one of the main chronic infectious diseases that endanger our human health. According to the statistics of the World Health Organization (WHO) in 2012, Mycobacterium tuberculosis (Mycobacterium, referred to as Mycobacterium tuberculosis) can cause about 1.4 million deaths worldwide every year, and the global epidemic is on the rise; It continues to appear and poses a serious health threat to human beings. Although chemotherapy is the basic treatment for tuberculosis, there are still problems such as low clearance rate of tuberculosis, long duration of treatment, high incidence of tuberculosis recurrence and drug-resistant tuberculosis, decline in lung function after chemotherapy, and chemical drugs Toxic and side effects are large, and there are varying degrees of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/898A61P11/00A61P31/06A61K31/722
CPCA61K31/722A61K36/185A61K36/21A61K36/264A61K36/536A61K36/8966A61K36/898A61K2300/00
Inventor 冒华
Owner 苏州瑞美科生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap